These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
33. Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients. Sullivan RJ; Hamid O; Gonzalez R; Infante JR; Patel MR; Hodi FS; Lewis KD; Tawbi HA; Hernandez G; Wongchenko MJ; Chang Y; Roberts L; Ballinger M; Yan Y; Cha E; Hwu P Nat Med; 2019 Jun; 25(6):929-935. PubMed ID: 31171876 [TBL] [Abstract][Full Text] [Related]
34. Sequential treatment with immunotherapy and BRAF inhibitors in BRAF-mutant advanced melanoma. Aya F; Fernandez-Martinez A; Gaba L; Victoria I; Tosca M; Pineda E; Gascon P; Prat A; Arance A Clin Transl Oncol; 2017 Jan; 19(1):119-124. PubMed ID: 27147251 [TBL] [Abstract][Full Text] [Related]
35. Activity and Resistance of a Brain-Permeable Paradox Breaker BRAF Inhibitor in Melanoma Brain Metastasis. Bonfill-Teixidor E; Iurlaro R; Handl C; Wichmann J; Arias A; Cuartas I; Emmenegger J; Romagnani A; Mangano L; Lorber T; Berrera M; Godfried Sie C; Köchl F; Eckmann J; Feddersen R; Kornacker M; Schnetzler G; Cicuendez M; Cordero E; Topczewski TE; Ferres-Pijoan A; González J; Martínez-Ricarte F; Muñoz-Couselo E; Tabernero J; Bischoff JR; Pettazzoni P; Seoane J Cancer Res; 2022 Jul; 82(14):2552-2564. PubMed ID: 35584009 [TBL] [Abstract][Full Text] [Related]
36. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials. Hauschild A; Larkin J; Ribas A; Dréno B; Flaherty KT; Ascierto PA; Lewis KD; McKenna E; Zhu Q; Mun Y; McArthur GA JAMA Oncol; 2018 Oct; 4(10):1382-1388. PubMed ID: 30073321 [TBL] [Abstract][Full Text] [Related]
37. BRAF V600E mutation and BRAF kinase inhibitors in conjunction with stereotactic radiosurgery for intracranial melanoma metastases. Xu Z; Lee CC; Ramesh A; Mueller AC; Schlesinger D; Cohen-Inbar O; Shih HH; Sheehan JP J Neurosurg; 2017 Mar; 126(3):726-734. PubMed ID: 27203149 [TBL] [Abstract][Full Text] [Related]
38. The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600. Massi D; Brusa D; Merelli B; Falcone C; Xue G; Carobbio A; Nassini R; Baroni G; Tamborini E; Cattaneo L; Audrito V; Deaglio S; Mandalà M Ann Oncol; 2015 Sep; 26(9):1980-1987. PubMed ID: 26037795 [TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma. Pires da Silva I; Zakria D; Ahmed T; Trojanello C; Dimitriou F; Allayous C; Gerard C; Zimmer L; Lo S; Michielin O; Lebbe C; Mangana J; Ascierto PA; Johnson DB; Carlino M; Menzies A; Long G J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35798536 [TBL] [Abstract][Full Text] [Related]
40. BRAFi/MEKi in patients with metastatic melanoma: predictive factors of complete response. Ribero S; Malavenda O; Fava P; Astrua C; Marra E; Osella-Abate S; Sanlorenzo M; Caliendo V; Fierro MT; Quaglino P Future Oncol; 2019 Jan; 15(2):133-139. PubMed ID: 30196713 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]